Evolution of Lung Cancer in the Context of Immunotherapy.
Immunotherapy, as a novel treatment, has brought new hope to many patients with cancer, including patients with lung cancer. However, the overall cure rate and survival rate of lung cancer are still not satisfactory. The process of evolution has improved the ability of tumors to adapt to immunothera...
| Publicado en: | Clinical Medicine Insights: Oncology Vol. 14; pp. 1 - 8 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Sage Publications Inc.
Jan-Dec2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=149210189&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 149210189 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11795549 B3KT jtl: Clinical Medicine Insights: Oncology issn: 11795549 maglogo: Y pubinfo: dt: Jan-Dec2020 vid: 14 pid: 344 pub: Sage Publications Inc. place: Thousand Oaks, California artinfo: ui: 149210189 149210189 149210189 10.1177/1179554920979697 149210189 ppf: 1 ppct: 7 formats: fmt: @attributes: type: P tig: atl: Evolution of Lung Cancer in the Context of Immunotherapy. aug: au: Sheng Yu Ruilin Wang Hong Tang Lili Wang Zhe Zhang Sen Yang Shuyue Jiao Xuan Wu Shuai Wang Mingyue Wang Cong Xu Qiming Wang Yufeng Wu affil: Department of Internal Medicine, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China sug: subj: Lung Neoplasms Diagnosis Lung Neoplasms Drug Therapy Immunotherapy Programmed Cell Death Protein 1 Receptor Antagonists and Inhibitors Drug Approval United States Food and Drug Administration Cell-Free Nucleic Acids Tyrosine Kinase Inhibitors Therapeutic Use Carcinoma, Non-Small-Cell Lung Drug Therapy ab: Immunotherapy, as a novel treatment, has brought new hope to many patients with cancer, including patients with lung cancer. However, the overall cure rate and survival rate of lung cancer are still not satisfactory. The process of evolution has improved the ability of tumors to adapt to immunotherapy, which induces drug resistance. Many studies have focused on immunoresistance and achieved meaningful results. Therefore, it is necessary to have an in-depth understanding of the current research progress in immunoresistance, which will help to achieve good clinical results more efficiently. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|